BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 10470224)

  • 1. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
    Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA
    Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 autoantibodies as tumor marker in head and neck squamous cell cancer.
    Gottschlich S; Hoffmann M; Maass JD; Görörgh T; Buhmann V; Hoffmann-Fazel A; Rudert H; Maune S
    Anticancer Res; 2003; 23(2A):913-5. PubMed ID: 12820322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-p53 antibodies in serum of smokers and head and neck cancer patients.
    Wollenberg B; Jan NV; Pitzke P; Reiter W; Stieber P
    Anticancer Res; 1997; 17(1A):413-8. PubMed ID: 9066686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The usefulness of new serum tumor markers in head and neck squamous cell carcinoma.
    Marcos CA; Martínez DA; de Los Toyos JR; Domínguez Iglesias F; Hermsen M; Guervós MA; Pendás JL
    Otolaryngol Head Neck Surg; 2009 Mar; 140(3):375-80. PubMed ID: 19248946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibody formation to cellular p53 protein in patients with squamous cell carcinomas of the upper respiratory and digestive system].
    Maass JD; Gottschlich S; Lippert BM; Niemann AM; Görögh T; Werner JA
    Laryngorhinootologie; 1996 Jan; 75(1):53-6. PubMed ID: 8851121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody responses to survivin and their clinical significance in patients with head and neck cancer.
    Eto M; Kodama S; Uemura N; Suzuki M
    Head Neck; 2007 Dec; 29(12):1128-35. PubMed ID: 17636541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head and neck cancer and p53-immunogenicity.
    Maass JD; Gottschlich S; Goeroegh T; Lippert BM; Werner JA
    Anticancer Res; 1997; 17(4B):2873-4. PubMed ID: 9329551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYFRA 8/18 in head and neck cancer.
    Maass JD; Niemann AM; Lippert BM; Gottschlich S; Folz BJ; Werner JA
    Anticancer Res; 1999; 19(4A):2699-701. PubMed ID: 10470223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
    Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
    Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
    Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
    Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The detection of quantitative serum p53 protein in lung cancer.
    Sen E; Gönüllü U; Akar N
    Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck.
    Lavieille JP; Lubin R; Soussi T; Reyt E; Brambilla C; Riva C
    Anticancer Res; 1996; 16(4C):2385-8. PubMed ID: 8816839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
    Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
    Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
    Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 autoantibodies from patients with head and neck cancer recognise common epitopes on the polypeptide chain of p53.
    Saleh J; Brunner C; Gölzer R; Nastainczyk W; Montenarh M
    Cancer Lett; 2006 Feb; 233(1):48-56. PubMed ID: 15913883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
    Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
    Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum anti-p53 antibodies in gastric cancer patients].
    Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
    Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
    Shimada H; Ochiai T; Nomura F;
    Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of p53 in tumor-distant epithelia of head and neck cancer patients is associated with an increased incidence of second primary carcinoma.
    Homann N; Nees M; Conradt C; Dietz A; Weidauer H; Maier H; Bosch FX
    Clin Cancer Res; 2001 Feb; 7(2):290-6. PubMed ID: 11234882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
    Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
    Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.